Search Results for: dg11

YHAHSN_logo

The New Faecal Calprotectin Care Pathway | NICE

The New Faecal Calprotectin Care Pathway, developed by Dr James Turvill, Consultant Gastroenterologist at York Teaching Hospitals NHS Foundation Trust, and implemented by the Yorkshire and Humber AHSN, supports the implementation of NICE guidance DG11, for the detection of inflammation in the bowel (i.e. IBS vs IBD). The innovative and sensitive pathway based will help

Continue Reading
Calprotectin Goes Mobile

Big Changes Coming Soon to a Clinic Near You

Calprotectin Testing Goes Mobile With advances in technology and the ubiquitous use of mobile devices, a huge opportunity has arisen to change the way some healthcare services are provided. This is especially applicable to the management of chronic conditions. With most people owning a mobile device or tablet this becomes a convenient way for patients to

Continue Reading

BÜHLMANN Quantum Blue®

Quantum Blue OverviewApplicationsBenefitsCase StudiesVideosPostersPublicationsQuantum Blue Overview In 2013 NICE published the DG11 guidance supporting the use of calprotectin as a cost-effective method to differentiate between IBD and IBS. Since that time, the level of testing within laboratories has increased significantly and BÜHLMANN has expanded its product portfolio to assist with evolving hospital requirements. BÜHLMANN offers
Continue Reading

Diagnosing IBD

Faecal calprotectin increases the diagnostic yield in patients with suspected small bowel disease – a multicenter retrospective cohort studyFaecal calprotectin testing increases the diagnostic yield of small bowel capsule endoscopy and may help identify patients at risk of small bowel disease. Abo El Ela et al. Swiss Medical Weekly March 2023  Faecal Calprotectin in Primary
Continue Reading

Calprotectin in Primary Care – Dr James Turvill

Dr. James Turvill, Consultant Gastroenterologist at York Teaching Hospital NHS Foundation Trust was one of the experts speaking at Alpha Laboratories Digestive Diseases Day in November 2017 where he discussed the application of calprotectin testing in clinical care. Since 2008 Dr. Turvill has developed a research interest in the use of biomarkers to facilitate in the

Continue Reading

Faecal calprotectin—ready for prime time?

Introduction Calprotectin is a heterodimer of calcium-binding proteins which belongs to the S-100 protein family. It is released from neutrophils and monocytes during cellular activation (or death) at sites of active inflammation, and accounts for upto 60% of the cytosolic protein in the granules of these cells. It is a highly stable protein, resists enzymatic

Continue Reading

NICE Calprotectin!

Faecal calprotectin testing hit the news headlines late last year following publication of the NICE diagnostic guidelines: ‘Faecal calprotectin diagnostic tests for inflammatory diseases of the bowel’ (DG11). Measurement of faecal calprotectin is considered to provide a reliable indicator of gastrointestinal (GI) tract inflammation and numerous studies show that, while faecal calprotectin concentrations are significantly

Continue Reading

Adoption project for Faecal Calprotectin Diagnostics Tests

In October 2013 NICE produced guidance (DG11) recommending the use of faecal calprotectin testing to help doctors distinguish between inflammatory bowel diseases, such as Crohn’s disease and ulcerative colitis, and non-inflammatory bowel diseases, such as irritable bowel syndrome. You can read more about the NICE guidelines here. The Health Technologies Adoption Programme (HTAP) are now

Continue Reading

About Calprotectin

Calprotectin is a protein biomarker that is present in the faeces when intestinal inflammation occurs. Faecal calprotectin testing is helping to improve patient care and save money for the NHS. It prevents the need for unnecessary endoscopy procedures on many patients by screening out those with Irritable Bowel Syndrome (IBS). The symptoms of functional disorders such
Continue Reading